research

Higher blood levels of the glial fibrillary acidic protein (GFAP) are significantly associated with shrinkage in certain brain regions of people with neuromyelitis optica spectrum disorder (NMOSD) who have antibodies against the AQP4 protein, a study showed. This association was not observed in people with myelin oligodendrocyte glycoprotein antibody-associated…

A blood test measuring levels of the GPR37 protein may help diagnose neuromyelitis optica spectrum disorder (NMOSD), assess disease severity, and monitor treatment response, according to a new study. The GPR37 test was also able to distinguish NMOSD from multiple sclerosis (MS) and other neurological disorders. “Our findings…

More than one-third of people with neuromyelitis optica spectrum disorder (NMOSD) have involuntary muscle contractions or movements, while about one-quarter develop a lack of motor coordination. That’s according to a systematic review of nearly 100 published studies, which found that individuals with NMOSD may experience a wide range of…

The gut hormone GLP-1 may contribute to brain inflammation in people with neuromyelitis optica spectrum disorder (NMOSD), leading to episodes of uncontrollable nausea, vomiting, or hiccups — a condition known as area postrema syndrome (APS), a new study suggests. These findings raise a crucial question about the use of…

The activity of an immune-regulating protein is significantly lower just before or during a relapse in people with neuromyelitis optica spectrum disorder (NMOSD), a recent study has found. This discovery could lead to new ways to monitor disease activity and develop treatments. The protein, called the aryl hydrocarbon receptor…

Long-term use of the approved therapy Enspryng (satralizumab) safely and effectively prevented relapses in people with neuromyelitis optica spectrum disorder (NMOSD) who have antibodies against aquaporin-4 (AQP4). That’s according to up to 8.8 years of pooled data from two placebo-controlled Phase 3 clinical trials — SAkuraStar (NCT02073279) and …

Nearly all adults with neuromyelitis optica spectrum disorder (NMOSD) experience headaches, especially migraines, a single-center study in Iran suggests. The presence of abnormalities in brain MRI scans and the use of the immunosuppressive therapy rituximab were each linked to an increased chance of new or worsening headaches after a…

Using noninvasive eye scans may help clinicians to determine if patients — particularly those in early disease stages — have neuromyelitis optica spectrum disorder (NMOSD) or multiple sclerosis (MS), both immune system disorders. That’s according to a review of published studies that together reveal that people with NMOSD…

The infusion therapy Ultomiris (ravulizumab-cwvz) safely and effectively reduces the risk of a relapse in complex cases of neuromyelitis optica spectrum disorder (NMOSD) and may be combined with rituximab for short periods, a case series study shows. For four NMOSD patients at a hospital in Fujiyoshida, Japan, Ultomiris…

Bio-Thera Solutions has closed patient enrollment ahead of schedule for a pivotal Phase 2/3 clinical trial in China of its investigational therapy BAT4406F due to the treatment’s “compelling efficacy” for neuromyelitis optica spectrum disorder (NMOSD). The decision is based on a recommendation from an Independent Data Monitoring Committee…